glp 1 agonist brand names india GLP-1 Drugs in India: 5× Market Growth by 2030 How GLP-1 medications are transforming

Ramnanan CJ, Edgerton DS, Kraft G, et al

Unlike sulfonylureas, which stimulate insulin secretion independently of blood glucose and can lead to hypoglycemia, GLP-1RAs improve glycemic control in a glucose-dependent manner, thereby minimizing the risk of hypoglycemia

Effects of tirzepatide on body weight GLP-1 receptor agonists, initially developed and marketed to exploit their relevant hypoglycemic effects, have shown positive but heterogeneous effects on body weight control

In many cases, such symptoms can be managed effectively through dietary changes (e.g., eating smaller meals more frequently, staying hydrated, increasing fiber intake, etc.)

The highest dose (2.4 mg of each agonist) decreased body weight in participants with overweight by 17% in 20 weeks 90

Inflammation in atherosclerosis: from pathophysiology to practice